No Data
Ensysce Biosciences To Carry Out 1-for-15 Reverse Stock Split On December 6th, 2024
Ensysce Biosciences Announces Partnership With Specialty Drug Manufacturer
Express News | Ensysce Biosciences Initiates PARtnership With A Drug Manufacturer For The Development And Commercial Launch Of PF614 And PF614-MPAR, Including A $10M Commitment From The Drug Manufacturer
Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Ensysce Biosciences Plans To Implement 1-For-15 Reverse Split Of Its Common Stock, Effective December 6, 2024
No Data
No Data
